ECHO-7 oncolytic virus Rigvir® in an adjuvant setting for stage I uveal melanoma; A retrospective case report
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Ophthalmology Case Reports"
DOI: 10.1016/j.ajoc.2020.100615
Abstract: Purpose To describe a case of choroidal melanoma treated with Rigvir® virotherapy in an adjuvant setting. Observations A female patient born in 1956 presented with a small choroidal melanoma in October 2007. 34 months after… read more here.
Keywords: adjuvant setting; virotherapy; uveal melanoma; case ... See more keywords
Cytolytic Properties and Genome Analysis of Rigvir® Oncolytic Virotherapy Virus and Other Echovirus 7 Isolates
Sign Up to like & getrecommendations! Published in 2022 at "Viruses"
DOI: 10.3390/v14030525
Abstract: Rigvir® is a cell-adapted, oncolytic virotherapy enterovirus, which derives from an echovirus 7 (E7) isolate. While it is claimed that Rigvir® causes cytolytic infection in several cancer cell lines, there is little molecular evidence for… read more here.
Keywords: cell; rigvir; echovirus isolates; analysis ... See more keywords
Effect of the oncolytic ECHO-7 virus Rigvir® on the viability of cell lines of human origin in vitro
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cancer"
DOI: 10.7150/jca.23242
Abstract: Background: The role of oncolytic viruses in cancer treatment is increasingly studied. The first oncolytic virus (Rigvir®, ECHO-7) was registered in Latvia over a decade ago. In a recent retrospective study Rigvir® decreased mortality 4.39-6.57-fold… read more here.
Keywords: viability; cell lines; effect; rigvir ... See more keywords